Combat COVID fast.
Enroll into the paid clinical trial.
Advancing COVID-19 care through research — and your participation.
Description: A multicenter, open-label, randomized Phase IIa study to evaluate the safety, efficacy, and pharmacokinetics of drug 83-0060 compared with standard therapy (Nirmatrelvir-Ritonavir / Paxlovid) in non-hospitalized adults with mild to moderate COVID-19.
Geography: Australia, Taiwan, South Korea, Uzbekistan
Sponsor: Trawsfynydd AU Pty Ltd (Australia)
Principal Investigator for Sponsor: Dr. Robert Redfield, MD, PhD
About the study
A novel small-molecule antiviral targeting the SARS-CoV-2 M-pro enzyme
Does not require ritonavir
Good tolerability and safety based on early data
What is the investigational product?
Are you eligible?
-
Eligible if:
• Adult (≥18 years) with confirmed SARS-CoV-2 infection (PCR or rapid test) within days before starting treatment
• COVID-19 symptoms began no more than 5 days before enrollment
• Mild or moderate disease (no hospitalization or oxygen therapy required)
• Agrees to comply with study visits, procedures, and use reliable contraception (if applicable)
-
Not eligible if:
• Requires hospitalization or intensive oxygen therapy
• Has severe liver or kidney impairment
• Has active viral infections (HBV, HCV, HIV) or other systemic infections
• Taking medications incompatible with Nirmatrelvir-Ritonavir
What to expect
Total duration: ~4 weeks
-
Screening & baseline tests
Eligibility review and initial health checks
-
5–10 days of treatment
Take the study medication as directed
-
Online visits
Check-ins with the study team via telehealth
-
Blood sampling (optional)
Helps researchers understand how the medication works
-
Final visit
Wrap-up and final assessments
Benefits and safety
Why participate?
Medical supervision
Contribution to the development of new COVID-19 therapies
Free tests and medications
Possible compensation
Voluntary participation
Study locations
In-person or remote
Countries: Australia, Taiwan, South Korea, Uzbekistan
Remote participation possible via telehealth
